Hysterectomy and Oophorectomy

Understanding Hysterectomy: What Gets Removed and Why It Matters#

A hysterectomy removes the uterus—the organ responsible for menstruation and pregnancy. For many transmasculine individuals, the monthly bleeding and the organ's symbolic association with assigned sex create profound dysphoria (TransHub, 2023). Removing it eliminates both the physical experience and the psychological weight of carrying reproductive anatomy that doesn't align with gender identity.

The term "hysterectomy" encompasses several variations, each with distinct implications for future health management. A total hysterectomy removes both the uterus and cervix, eliminating the need for future Pap smears (unless there's a history of cervical dysplasia) and preventing any possibility of cervical stump complications (ACOG, 2022). This represents the standard approach for gender-affirming surgery (Jeftovic et al., 2018). A supracervical hysterectomy, also called partial or subtotal hysterectomy, removes the uterus while leaving the cervix intact. This variation was once thought to preserve sexual function, but multiple randomized controlled trials have found no difference in sexual outcomes compared to total hysterectomy (Lethaby et al., 2012). The cervix retention does carry documented consequences: 5–20% of patients experience persistent cyclic bleeding from the cervical stump, and reoperation rates exceed 20% due to cervical stump complications including bleeding, pain, and dysplasia (Learman et al., 2003). Cervical cancer screening must also continue indefinitely when the cervix is retained (ACOG, 2022).

Given these findings, most surgeons performing gender-affirming surgery recommend total hysterectomy unless specific medical circumstances favor cervical preservation (University of Utah Health, 2024). The small theoretical advantage in sexual function has not materialized in research (Lethaby et al., 2012), while the documented disadvantages create ongoing medical management needs that most patients would prefer to avoid.

Oophorectomy: Deciding About the Ovaries#

While hysterectomy addresses the uterus, oophorectomy involves the ovaries—the organs producing estrogen, progesterone, and approximately half of the body's testosterone in premenopausal individuals (Medscape, 2024). The decision about ovarian removal carries significant hormonal and health implications that extend far beyond the surgical recovery period.

Bilateral salpingo-oophorectomy (BSO) removes both ovaries and fallopian tubes, eliminating endogenous estrogen and progesterone production and inducing surgical menopause (New York Gynecology Surgery, 2024). This represents the most common choice for transmasculine individuals pursuing gender-affirming surgery because it eliminates the need for testosterone to suppress ovarian function continuously (UCSF Transgender Care, 2023). After bilateral oophorectomy, exogenous testosterone provides all hormone replacement needs without working against persistent estrogen production. Many find the hormonal simplicity appealing: no more menstrual bleeding, no cycling symptoms, and more stable testosterone levels (TransHub, 2023).

Unilateral oophorectomy removes one ovary while preserving the other, maintaining approximately half of normal ovarian function. This option appeals to individuals uncertain about lifelong hormone therapy or those preserving fertility options. Complete ovarian preservation leaves both ovaries intact, continuing natural hormone production (University of Utah Health, 2024). This path makes sense for people planning pregnancy, those with medical contraindications to testosterone, or individuals who prefer maintaining endogenous hormone production.

The trade-offs deserve careful consideration grounded in medical evidence. Removing both ovaries before natural menopause causes an abrupt loss of ovarian hormone production, so people need an individualized plan with their surgical and hormone-prescribing teams for adequate sex-hormone replacement and bone-health monitoring. In an 18-month observation cohort of high-risk premenopausal women after oophorectomy, mean bone mineral density decreased 8.5% at the lumbar spine and 5.7% at each hip; that cohort does not establish a 24-month osteopenia or osteoporosis prevalence for transmasculine patients (Hibler et al., 2016). In a population-based cohort of women, bilateral oophorectomy before age 45 was associated with higher cardiovascular mortality; the study's estrogen-treatment finding does not directly estimate risk for transgender men on testosterone (Rivera et al., 2009). However, for transmasculine individuals already committed to lifelong testosterone therapy, bilateral oophorectomy simply shifts the hormone source from internal to external while eliminating unwanted estrogen effects (Chen et al., 2023).

Surgical Approaches: How the Surgery Gets Done#

Four distinct surgical approaches exist for performing hysterectomy and oophorectomy, each with specific advantages, disadvantages, and recovery profiles. Understanding these differences helps in discussing options with surgeons and setting realistic expectations.

Vaginal hysterectomy removes the uterus through the vaginal canal without any abdominal incisions. The American College of Obstetricians and Gynecologists recommends this as the first-choice approach whenever feasible (ACOG, 2017). The advantages are substantial: fastest recovery with return to normal activities in 24–38 days, lowest complication rates across all approaches, no visible scarring, and often same-day discharge (Aarts et al., 2015). For transmasculine individuals planning future phalloplasty, vaginal hysterectomy offers particular advantages because it preserves abdominal anatomy and blood vessel access needed for microvascular genital reconstruction. The surgical planes remain undisturbed by previous abdominal surgery, and the blood supply to the lower abdomen remains intact without scarring that might complicate later procedures.

Not everyone qualifies for vaginal hysterectomy. Factors limiting feasibility include very large uteri (typically over 280 grams), limited vaginal access due to anatomy or testosterone-induced changes, extensive pelvic adhesions from prior surgery or endometriosis, or lack of uterine mobility. Surgeons evaluate these factors during pre-operative examination.

Laparoscopic hysterectomy involves three to four small abdominal incisions (5–12mm each) through which surgical instruments and a camera enter the abdomen. The surgeon operates while viewing a magnified video screen. This approach offers return to normal activities in 22–25 days with same-day or overnight hospital discharge, excellent visualization for complex cases, and the ability to address other abdominal pathology if discovered (Aarts et al., 2015). The small incisions heal quickly and leave minimal scarring.

Laparoscopic surgery does carry a slightly higher risk of urinary tract injury—approximately 0.2–2% compared to 0.2% for abdominal hysterectomy—related to the limitations of working through small incisions with instruments that provide less tactile feedback than traditional surgery (Aarts et al., 2015). The technique also requires significant surgical skill, with learning curves of 50–75 cases before surgeons achieve optimal outcomes. Complication rates of 5.3% fall between vaginal (lowest) and abdominal (highest) approaches (Aarts et al., 2015).

Robotic-assisted hysterectomy employs the da Vinci Surgical System, a sophisticated robot controlled by the surgeon from a console. The system provides 3D visualization, instruments with seven degrees of motion (exceeding human wrist mobility), and tremor filtration. These technological advantages theoretically improve precision and reduce complications. In practice, multiple large studies comparing robotic to conventional laparoscopic hysterectomy have found no significant difference in outcomes, complications, or recovery time (Chen et al., 2017). The robotic approach does add approximately $2,000 in costs per procedure related to equipment and longer operative times. For gender-affirming surgery, the choice between laparoscopic and robotic approaches often comes down to surgeon preference and facility equipment rather than meaningful outcome differences.

Abdominal hysterectomy requires a five to seven inch incision through the abdominal wall, typically made horizontally above the pubic bone (similar to cesarean section) or vertically from pubic bone toward navel. This open surgery approach is reserved for very large uteri (typically over 750 grams), suspected malignancy requiring extensive staging, or severe adhesive disease from prior surgery or endometriosis that makes minimally invasive approaches unsafe. Recovery takes substantially longer—37–42 days return to normal activities—with hospital stays averaging two to four days and blood loss 2.8 times higher than minimally invasive approaches (Aarts et al., 2015). Complication rates range from 10–22% depending on complexity.

For straightforward gender-affirming surgery in patients without complex medical histories, vaginal or laparoscopic approaches represent optimal choices. A 2018 study specifically comparing surgical approaches in transgender men found that vaginal hysterectomy showed advantages in operative time, blood loss, and postoperative recovery, identifying it as the "optimal choice" for gender-affirming surgery when feasible (Jeftovic et al., 2018).

Meeting the Requirements: WPATH Standards and Insurance Criteria#

The WPATH Standards of Care Version 8, published in September 2022, substantially reduced barriers to gender-affirming surgery compared to previous versions. Understanding both the clinical recommendations and insurance requirements helps navigate the authorization process successfully.

WPATH criteria for hysterectomy and oophorectomy include persistent, well-documented gender incongruence; capacity to consent to treatment; understanding of reproductive effects including permanent infertility; and assessment confirming that mental and physical health conditions have been evaluated with risks and benefits discussed. Crucially, hormone therapy is not required before hysterectomy or oophorectomy under WPATH standards—this distinguishes these procedures from genital reconstruction surgeries like metoidioplasty or phalloplasty, which require testosterone exposure for adequate tissue development (Coleman et al., 2022).

One letter from a qualified healthcare professional is now the WPATH standard, reduced from the two letters required under SOC 7. The assessor can be a mental health provider (psychologist, psychiatrist, licensed clinical social worker, licensed marriage and family therapist, licensed professional counselor) or a medical provider with specific training in transgender health (Coleman et al., 2022). However, many insurance companies have not updated their requirements to match the new standards. Many still require two letters, and verification with specific insurance plans remains essential before starting the authorization process.

The previous requirement for 12 months of "living in the gender role" has been eliminated from WPATH standards. While a minimum of six months of stable hormone therapy is suggested when someone plans to undergo hormone therapy—reduced from 12 months in SOC 7—this represents a recommendation rather than a requirement (Coleman et al., 2022). Age limits were removed from the final published SOC 8, with decisions made individually based on capacity to consent and maturity. Most institutions continue to require age of majority (18 in most U.S. jurisdictions, though this varies internationally) as a practical matter of surgical risk management and consent law.

Mental health assessments serve to confirm gender incongruence, evaluate readiness for surgery, assess mental health status and any conditions potentially affecting outcomes, document informed consent capacity, confirm understanding of reproductive effects, and evaluate support systems and recovery resources. The informed consent model is explicitly supported in WPATH SOC 8, positioning mental health involvement as therapeutic support rather than gatekeeping. The assessment should help individuals make informed decisions aligned with their values and goals, not serve as a barrier that assumes transgender people cannot make autonomous medical decisions.

Insurance authorization typically requires diagnosis of gender dysphoria (ICD-10 code F64.0), documentation demonstrating WPATH criteria are met, prior authorization submitted before scheduling surgery, and mental health clearance letters with specific required language. Many plans continue to require 12 months of documented continuous hormone therapy despite updated WPATH guidance. Common denial reasons include gender marker mismatches in medical records (such as "female" listed when patient identifies as male), incomplete documentation, or explicit transgender exclusions in plan language. Many states now prohibit such exclusions in health insurance plans, though self-funded employer plans may be exempt from state insurance mandates under ERISA preemption.

For appeals when insurance denies coverage, submit additional documentation within 180 days of denial. If denied again at the internal appeal level, external review by an independent third party can be requested—and results of external review are binding on the insurer. Relevant CPT procedure codes include 58260–58262 for vaginal hysterectomy, 58541–58554 for laparoscopic hysterectomy with various modifications, and 58275 for vaginal hysterectomy with vaginectomy (if performed).

Preparing for Surgery: Physical and Medical Optimization#

Pre-operative preparation significantly impacts surgical outcomes and recovery. Several weeks before surgery, patients should focus on optimizing overall health and completing required medical clearances.

Smoking cessation at least four to six weeks before surgery is non-negotiable. Nicotine constricts blood vessels, impairs wound healing, increases infection risk, and significantly elevates complication rates. Many surgeons require nicotine testing before proceeding, and positive results lead to surgery postponement. This includes cigarettes, cigars, vaping, nicotine patches or gum, and smokeless tobacco.

For patients with diabetes, blood sugar control must be optimized with hemoglobin A1c ideally below 7%. Uncontrolled diabetes dramatically increases infection risk and impairs healing. Medical clearance typically includes complete blood count, comprehensive metabolic panel, and sometimes additional testing based on age and health history. Patients over 40 may need an EKG, and those with cardiac or pulmonary conditions require clearance from relevant specialists.

Body mass index requirements vary by institution. While some surgical centers set cutoffs at 30–35, research increasingly shows these thresholds lack strong evidence, and many centers now use individualized assessment rather than arbitrary limits. Higher BMI does correlate with longer operative times and slightly increased complication rates, but many patients with elevated BMI undergo successful surgery when other health parameters are optimized.

Testosterone management has evolved significantly in recent years and deserves detailed discussion. Traditional surgical practice called for stopping testosterone two to four weeks before surgery due to theoretical blood clot risk. The logic was straightforward: testosterone increases red blood cell production (raising hematocrit), and higher hematocrit theoretically increases thrombotic risk. However, multiple large studies have now examined this question directly. A 2018 analysis in JAMA Surgery found no significant difference in complication rates between transgender patients who continued versus stopped hormone therapy perioperatively (Boskey et al., 2019). A 2022 Cleveland Clinic study of 178 transgender patients undergoing various surgeries found venous thromboembolism rates of 0% in those continuing hormones compared to 1.1% in those stopping—suggesting if anything, hormone continuation might be protective (Nolan et al., 2022).

Current UCSF guidelines for transgender health explicitly state: "There is no need to stop testosterone before surgery" (UCSF Transgender Care, 2023). WPATH SOC 8 similarly does not mandate testosterone cessation. Despite this evolving evidence, individual surgeon preferences vary widely. The decision should be individualized based on personal clotting risk factors—including prior blood clots, inherited clotting disorders, obesity, smoking, and immobility. The process of stopping and restarting testosterone can cause significant mood swings, hot flashes, dysphoria, and physical discomfort. For many, the psychological toll of temporarily losing testosterone outweighs the uncertain theoretical benefit.

Blood thinners and anti-platelet medications require careful management. Warfarin should stop five days before surgery with INR checked pre-operatively; direct oral anticoagulants (Xarelto, Eliquis, Pradaxa) should stop one to three days before depending on kidney function and bleeding risk; aspirin should stop seven to ten days before; and NSAIDs including ibuprofen should stop two weeks before surgery. Herbal supplements including ginkgo biloba, garlic supplements, and St. John's wort should stop two weeks prior due to bleeding and drug interaction risks.

For transmasculine patients on testosterone, pre-operative vaginal estrogen represents an important but often overlooked preparation. Testosterone causes vaginal atrophy similar to menopause—the vaginal epithelium becomes thinner, drier, and more fragile. This testosterone-induced change creates specific surgical considerations. One study found patients on testosterone have 3.3 times higher risk of vaginal laceration requiring intraoperative repair compared to patients not on testosterone (Morrison et al., 2022). Vaginal estrogen cream (typically one gram intravaginally three times weekly for two to four weeks before surgery) significantly improves tissue quality without reversing masculinization—systemic absorption remains minimal. Many surgeons also prescribe metronidazole 500mg twice daily the day before surgery, as patients on testosterone have higher rates of bacterial vaginosis, and pre-operative treatment reduces post-operative infection risk.

Bowel preparation protocols have become less stringent based on recent research. Multiple randomized controlled trials demonstrate that mechanical bowel preparation is not required for laparoscopic hysterectomy and offers no advantage over simple fasting (Muzii et al., 2016). A fasting-only approach—eating a light breakfast the day before surgery, transitioning to clear liquids, and nothing by mouth after midnight—proves equally effective without the discomfort of bowel cleansing. Under enhanced recovery after surgery (ERAS) protocols, clear liquids may continue until two hours before arrival time. Individual surgeon protocols vary, so following specific instructions provided remains essential.

The Day of Surgery: What Happens in the Operating Room#

On surgery day, patients typically arrive two hours before scheduled start time for registration, pre-operative preparation, and anesthesia consultation. The anesthesia team reviews medical history, discusses anesthesia approach, and answers questions. An IV is placed, and pre-operative antibiotics are administered—typically cefazolin plus metronidazole to reduce infection risk. Sequential compression devices are placed on the legs; these intermittently inflate and deflate throughout surgery to prevent blood clot formation during immobility.

The anesthesia team induces general anesthesia through IV medications, inserts a breathing tube to protect the airway, and maintains unconsciousness throughout the procedure. Patients remember nothing from the point of medication administration until waking in recovery.

For vaginal hysterectomy, the surgeon works entirely through the vaginal canal. The cervix is grasped and pulled downward, creating tension that helps identify surgical planes. The bladder is carefully dissected away from the front of the cervix and uterus. The peritoneum (abdominal lining) is opened, providing access to the space around the uterus. The uterine arteries on each side are clamped, cut, and sutured to prevent bleeding. The connections between the uterus and surrounding structures are methodically divided. If oophorectomy is planned, the surgeon brings each ovary and fallopian tube down through the vagina for removal. Finally, the peritoneum is closed, and the vaginal cuff (the top of the vagina where the cervix was attached) is sutured. The entire procedure typically takes 45–75 minutes.

For laparoscopic hysterectomy, three to four small incisions (5–12mm) are made in the abdomen. Carbon dioxide gas inflates the abdomen, creating space for instruments and visualization. A camera inserts through one incision, projecting magnified images onto video screens. Surgical instruments enter through remaining incisions. The surgeon identifies anatomical structures, carefully dissects the bladder away from the uterus, and identifies ureters (tubes carrying urine from kidneys to bladder) to avoid injury. The blood supply to the uterus is sealed using electrocautery or specialized sealing devices. For laparoscopic hysterectomy, the vaginal cuff is typically closed laparoscopically using sutures visible on the video screen, though some surgeons close it vaginally. If oophorectomy is planned, the ovaries and fallopian tubes are freed from their attachments and removed through one of the small incisions or through the vagina. The entire procedure typically takes 60–90 minutes.

Robotic-assisted hysterectomy follows the same general steps as laparoscopic surgery, but the surgeon sits at a console away from the operating table, controlling robotic instruments that provide enhanced visualization and movement. The procedure takes slightly longer—typically 75–120 minutes—due to docking time for the robot and the learning curve for surgical teams.

Abdominal hysterectomy begins with an incision through skin, subcutaneous fat, and fascia (the tough connective tissue covering muscles), then carefully separating or cutting through abdominal muscles to reach the peritoneal cavity. Once inside the abdomen, the steps mirror those of laparoscopic surgery but with direct hand-operated instruments rather than long laparoscopic tools. The larger incision provides excellent visualization and easier access for challenging cases. After removing the uterus and ovaries (if indicated), the surgeon closes the incision in layers—peritoneum, fascia, subcutaneous tissue, and skin. This approach typically takes 90–120 minutes.

Throughout all approaches, the urinary catheter typically inserted before surgery is usually removed before leaving the operating room or shortly after in recovery. Patients are encouraged to urinate independently within six to eight hours after surgery. Difficulty urinating affects up to 60% of patients temporarily, usually resolving within one to two weeks. If prolonged urinary retention occurs, temporary catheterization may be needed.

The First Days and Weeks: Recovery at Home#

Recovery in the hospital post-anesthesia care unit lasts one to three hours. During this time, pain management begins (typically IV medications transitioning to oral medications), vital signs are monitored, and providers assess readiness for discharge. For minimally invasive approaches, same-day discharge is increasingly common. Scheduling surgery early in the day helps ensure adequate recovery time for safe same-day release. Some patients require overnight observation—typically those with nausea, inadequate pain control, or medical conditions requiring monitoring.

Discharge instructions typically include prescriptions for pain medications (often oxycodone or hydrocodone for a few days), anti-nausea medication, stool softener to prevent constipation from pain medications and post-surgical changes, and sometimes antibiotics if infection risk is elevated. Signs requiring immediate medical attention include fever over 100.4°F, heavy vaginal bleeding soaking through more than one pad per hour, severe abdominal pain not controlled by medications, inability to urinate, chest pain or shortness of breath, or leg swelling with pain. Many of these symptoms could indicate serious complications requiring emergency evaluation.

Pain management in the first few days typically requires scheduled opioid medications for moderate to severe pain, transitioning to acetaminophen and ibuprofen (after the two-week NSAID restriction ends) by the end of the first week. Most patients reduce opioid use substantially by day three to five and stop by the end of the first week. Abdominal cramping is normal as the internal healing begins. Heating pads on a low setting can provide comfort, though they should not be placed directly on incisions.

Activity restrictions follow a progressive timeline designed to protect healing tissues while preventing complications from immobility. Walking is encouraged starting the day of surgery—even just to the bathroom initially, gradually increasing distance and frequency. Walking reduces blood clot risk and promotes bowel function recovery. Light activity including showering, dressing, and light meal preparation can resume immediately but should not cause pain or exhaustion. Heavy lifting over 10–15 pounds should be avoided for at least six weeks to prevent the internal sutures from pulling apart. Stairs can be managed as needed, though patients should move slowly and carefully, particularly in the first few days when pain medications cause drowsiness. Return to work depends on job requirements: desk jobs typically allow return at two weeks, while jobs requiring standing, walking, or lifting may require four to six weeks.

Driving should wait until patients are no longer taking narcotic pain medications and can perform emergency braking maneuver (slamming on brakes with full force) without hesitation or pain—typically two to four weeks. Exercise restrictions are progressive: walking can increase gradually without specific limitations, light exercise like stationary cycling or swimming can begin at four weeks with surgeon approval, and high-intensity exercise including running, heavy weights, or contact sports requires surgeon clearance at six to eight weeks.

The concept of pelvic rest is critical and bears emphasis. Nothing should enter the vagina for six to twelve weeks (specific timeframe per surgeon instructions). This means no tampons, no douching, no fingers, no sex toys, no penises. The vaginal cuff where the uterus was removed must heal completely before any penetration. Failure to observe pelvic rest significantly increases risk of vaginal cuff dehiscence—a serious complication where the surgical closure separates, potentially allowing bowel to protrude through the vagina. Light vaginal bleeding or spotting is normal for up to six weeks, gradually decreasing over time. Heavier bleeding, particularly after the first two weeks, warrants evaluation.

Emotional responses during recovery vary widely. Many patients experience profound relief that menstruation will never return and that dysphoria-inducing organs are gone. Some feel surprisingly emotional or weepy in the days after surgery—partly from the physical stress of surgery, partly from anesthesia aftereffects, and partly from hormonal shifts if ovaries were removed. These feelings typically resolve within a few days to weeks. For patients experiencing difficulty with the recovery emotionally, reaching out to mental health providers, support groups, or trusted friends proves valuable.

Hormonal Changes and Testosterone Management After Oophorectomy#

Understanding what happens hormonally after bilateral oophorectomy helps set realistic expectations and guides appropriate management. The ovaries produce approximately 80% of the body's estrogen (estradiol), about 25% of its testosterone, and all of its progesterone in premenopausal individuals. When both ovaries are removed, these hormones drop precipitously within hours.

For cisgender women or individuals not on testosterone, bilateral oophorectomy causes immediate surgical menopause with symptoms including hot flashes, night sweats, mood changes, vaginal dryness, decreased libido, sleep disturbances, and cognitive changes. The sudden hormone drop—unlike natural menopause which occurs gradually over four to ten years—can create intense symptoms requiring hormone replacement therapy.

For transmasculine individuals already on testosterone, the clinical picture differs substantially. Research from 2023 examining hormone levels before and after hysterectomy with bilateral oophorectomy in transgender men found that total testosterone levels do not significantly change post-operatively when patients remain on the same testosterone dose (Chen et al., 2023). The exogenous (external) testosterone continues providing hormone replacement. Estradiol levels do drop substantially but remain higher than typical postmenopausal levels due to aromatization—the biochemical conversion of testosterone to estradiol in fat tissue.

This leads to a critical clinical question: do transmasculine patients need testosterone dose adjustments after bilateral oophorectomy? The answer is more nuanced than simple yes or no. Most patients do not need routine testosterone dose adjustments. A multicenter 2023 study of 308 transgender men found that only 8% changed their testosterone dosing after hysterectomy, and those who underwent bilateral oophorectomy were no more likely to change doses than those who didn't (Klein et al., 2023). A systematic review examining this question concluded that "current evidence does not support regular reduction in testosterone dosing following oophorectomy" (Chen et al., 2023).

However, individual responses vary. Some patients perceive testosterone as "stronger" or experiencing intensified effects after bilateral oophorectomy—likely because estrogen's counterbalancing effects are removed rather than because testosterone levels increase. Symptoms suggesting testosterone may be relatively high include worsening acne, significantly increased oiliness of skin or hair, heightened irritability or mood volatility, or aggression. These symptoms may warrant dose reduction, typically by 10–20% initially with reassessment at three months.

A small minority of transmasculine individuals on testosterone still experience vasomotor symptoms (hot flashes and night sweats) despite adequate testosterone levels. A single case report described a transgender man who developed severe frequent symptoms after hysterectomy and oophorectomy while taking testosterone; increasing or splitting testosterone and trying venlafaxine did not relieve the symptoms. In that case, transdermal estradiol relieved symptoms without reported loss of masculinization (Casimiro & Cohen, 2019). A case report cannot estimate how often this occurs or prescribe treatment; persistent vasomotor symptoms warrant individualized clinical assessment.

Hormone monitoring should occur at three and six months during any dose adjustment period, then annually once stable (Endocrine Society, 2017). Key laboratory tests include total testosterone with target range of 300–1000 ng/dL (most providers aim for 500–600 ng/dL), hematocrit which must remain below 54% to avoid increased clot and stroke risk, and lipid panel since testosterone can modestly increase LDL cholesterol (Endocrine Society, 2017). Estradiol monitoring isn't routinely necessary unless ovarian remnant syndrome is suspected or vasomotor symptoms persist despite adequate testosterone (Chen et al., 2023).

Sexual Function, Vaginal Health, and Intimacy After Surgery#

Sexual function after hysterectomy has been extensively studied, with findings that contradict many assumptions. A 2014 systematic review found that 77–97% of women report either improvement or no change in sexual function one year post-hysterectomy, with improvements most pronounced when surgery relieved pain or bleeding that had interfered with sex (Lonnée-Hoffmann & Pinas, 2014). For transgender individuals, additional dimensions relate to dysphoria reduction and testosterone effects on sexual function.

The PRIDE Study published in 2023, examining 1,219 transgender men and gender-diverse individuals assigned female at birth, found that over 60% of those on testosterone experience vulvovaginal pain during sexual activity—this predates surgery and continues or improves after hysterectomy depending on management (Radix et al., 2023). Pain most commonly occurs in the vagina (52% of those experiencing pain), around the clitoris (29%), and at the labia (25%). Testosterone causes vaginal atrophy through mechanisms identical to menopause: thinning epithelium, decreased lubrication, elevated vaginal pH, and increased susceptibility to micro-tears and infections (Morrison et al., 2022).

Vaginal estrogen (cream, tablet, or ring) is safe for transmasculine individuals on testosterone with minimal systemic absorption that does not reverse masculinization (UCSF Transgender Care, 2023). Multiple studies confirm vaginal estrogen maintains systemic estradiol in the typical male range while dramatically improving local tissue health (Morrison et al., 2022). Water-based lubricants should be used liberally during penetrative activity. Pelvic floor physical therapy addresses muscle tension contributing to pain and teaches relaxation techniques (UCSF Transgender Care, 2023).

A survey of 118 transgender men post-hysterectomy found 56% reported no change in orgasms, 25% reported sexual response was better, and 11% described experiences as "different"—often attributed to increased body comfort (TransHub, 2023). The debate about cervical orgasms has been addressed by randomized trials: no significant difference in sexual satisfaction exists between total and supracervical hysterectomy (Lethaby et al., 2012).

Satisfaction with gender-affirming surgery outcomes is exceptionally high. A meta-analysis of 27 studies with 7,928 patients found a pooled regret rate of 1%, with transmasculine surgeries showing under 1% regret (Bustos et al., 2021). A 2023 study of 1,989 patients found 99.7% satisfaction, with only 5 patients (0.3%) expressing regret—all citing social factors rather than surgical dissatisfaction (OHSU, 2023). Studies consistently document improvements in self-confidence, relationships, body image, and mental health (Bustos et al., 2021).

Recognizing and Managing Complications#

While hysterectomy is generally safe, understanding potential complications allows prompt recognition and treatment. Overall complication rates vary by approach: 2–3% for vaginal, 5.3% for laparoscopic, and 10–22% for abdominal hysterectomy (Aarts et al., 2015).

Vaginal cuff dehiscence—separation of the surgical closure—occurs in 0.14–4.1% of cases, with higher rates after laparoscopic approaches (Exxcellence in Gynecology, 2024). Risk factors include tobacco use, vaginal atrophy, early sexual activity resumption, and excessive electrocautery (Exxcellence in Gynecology, 2024). Warning signs include sudden pelvic pain (present in 58–100% of cases), vaginal bleeding, watery discharge, or sensation of something "falling out." If bowel is visible, this constitutes a surgical emergency requiring immediate care (Exxcellence in Gynecology, 2024).

Infection affects 9–13% of patients (Aarts et al., 2015). Vaginal cuff cellulitis presents with increasing pain and purulent discharge 3–10 days post-discharge, responding to oral antibiotics. Pelvic cellulitis appears 5–10 days post-surgery with fever exceeding 100.4°F, requiring IV antibiotics (ACOG, 2017). Contact your surgeon for fever above 100.4°F, increasing pain, purulent discharge, or incision redness and swelling.

Adhesions (internal scar tissue) form in 2–3% of cases and can cause chronic pelvic pain, painful intercourse, or bowel complications (IntechOpen, 2023). Prevention includes minimally invasive techniques, careful tissue handling, and adhesion barriers (IntechOpen, 2023). Treatment involves pelvic floor physical therapy, pain management, or surgical adhesiolysis.

Ovarian remnant syndrome occurs when functional ovarian tissue remains after intended complete removal, causing pelvic pain, cyclical symptoms, or absence of expected menopausal symptoms (Wikipedia, 2024). Risk factors include pre-existing adhesions and endometriosis (present in 50% of cases) (Wikipedia, 2024). Diagnosis involves hormonal testing showing premenopausal FSH levels and imaging. Treatment is surgical excision.

Blood clots affect 0.3–0.7% of patients, with highest risk in the first two weeks (Aarts et al., 2015). Prevention includes compression devices, early mobilization, and adequate hydration (Nicolaides et al., 2013). Warning signs of deep vein thrombosis include unilateral leg swelling, pain, and warmth. Pulmonary embolism symptoms—sudden shortness of breath, sharp chest pain, rapid heartbeat, or coughing blood—require emergency care (Nicolaides et al., 2013).

Bladder dysfunction affects up to 60% of patients temporarily, with most resolving within two weeks (Toronto MIGS, 2024). Nerve injury affecting bowel or bladder is rare (under 0.5%). Chronic pain affects 5–32% of patients depending on definitions, with causes including adhesions, nerve injury, or pelvic floor dysfunction (IntechOpen, 2023).

Long-Term Health Monitoring and Preventive Care#

Cancer screening requirements depend on structures removed. If the cervix was removed for benign conditions, Pap smears are no longer needed (ACOG, 2022). If retained, standard cervical cancer screening continues. With cervical dysplasia history, annual vaginal cytology continues for 20 years (ACOG, 2022).

Bone density requires attention after oophorectomy. In one 18-month observation cohort of high-risk premenopausal women after oophorectomy, mean bone mineral density decreased 8.5% at the lumbar spine and 5.7% at each hip; that result is not a 24-month osteopenia/osteoporosis prevalence estimate and is not transmasculine-specific (Hibler et al., 2016). Adequate testosterone therapy maintains bone density in transgender men—testosterone aromatizes to estradiol providing bone protection (Endocrine Society, 2017). Baseline DEXA scan is recommended within two years of bilateral oophorectomy before age 50, repeated every two years if normal (NOF, 2024). Calcium 1000–1200mg daily and vitamin D 800–1000 IU support bone health (NOF, 2024).

Cardiovascular health monitoring is important after bilateral oophorectomy before age 45. In a population-based cohort of women, bilateral oophorectomy before age 45 was associated with higher cardiovascular mortality, particularly among those not treated with estrogen through age 45 or longer; that cohort does not directly estimate risk for transgender men on testosterone or define an individual hormone regimen (Rivera et al., 2009). For transgender men on testosterone, the picture is complex—testosterone may modestly increase LDL and blood pressure but large cohort studies have not shown increased cardiovascular events (Endocrine Society, 2017). Regular blood pressure checks (at least annually) and lipid panels every one to two years help identify problems early.

Preserving Fertility Before Surgery#

Fertility preservation options should be discussed before surgery, as bilateral oophorectomy permanently ends egg production.

Oocyte (egg) cryopreservation involves controlled ovarian stimulation for 10–14 days followed by transvaginal retrieval. The process requires two to four weeks minimum before surgery. Costs range from $8,000–20,000 per cycle plus $3,000–5,000 for medications and $500–1,000 annually for storage (Labry Fertility, 2024). Success rates decline with age: under 35, approximately 63% live birth rate per thaw with adequate egg numbers; over 40, approximately 18% (Wikipedia, 2024). Fertility specialists recommend retrieving 15–25 mature eggs for realistic success.

Transgender men can pursue egg freezing while on testosterone, though most resume menstruation within six months of stopping (Cryologyx, 2024). The transvaginal ultrasounds involved may be dysphoria-inducing.

Embryo freezing offers higher success rates—50–60% pregnancy rates with 95% embryo survival (Wikipedia, 2024). However, it requires a partner or sperm donor. Costs are similar to egg freezing plus potential sperm donor costs.

Ovarian tissue cryopreservation remains experimental but can be performed at oophorectomy without separate stimulation cycle (Cryologyx, 2024). Success rates are lower—30–40% live birth rate—and availability is limited (Cryologyx, 2024). Cost is $5,000–15,000 depending on institution.

Insurance Coverage, Costs, and Financial Navigation#

Most major private insurers now cover gender-affirming surgery when medical necessity is documented (TransHealthCare, 2024). Medicare covers gender-affirming surgery following National Coverage Determination effective 2014 (TransHealthCare, 2024). Medicaid coverage varies: as of 2022, 26 states plus DC explicitly cover gender-affirming surgery (Global News, 2022). State mandates have expanded coverage—currently 25 states prohibit transgender exclusions in state-regulated plans.

Coverage typically requires diagnosis of gender dysphoria (ICD-10 code F64.0), documentation demonstrating WPATH criteria are met, prior authorization, and mental health clearance letters (Headway, 2024). Many plans require 12 months of documented hormone therapy despite updated WPATH guidance (TransHealthCare, 2024). Common denial reasons include gender marker mismatches, incomplete documentation, or explicit exclusions.

Appeals follow a structured process. First-level internal appeal must be filed within 180 days—submit additional documentation including detailed provider letters, peer-reviewed literature, and functional impairment documentation. If denied, external review by an independent third party can be requested—results are binding in most states (TransHealthCare, 2024).

Uninsured costs range from $10,000–22,500 for laparoscopic hysterectomy, with bilateral oophorectomy adding $6,000–10,000 (Healthcare Bluebook, 2024). This includes surgeon fees, anesthesiology, facility fees, and pathology. Geographic variation is substantial—costs in major metropolitan areas run 40–60% higher than lower cost-of-living areas.

Considerations for Neurodivergent Individuals and Those with Disabilities#

Transgender individuals are 4–7 times more likely to be autistic than the cisgender population, with 4.8–26% of gender clinic patients having autism diagnoses (Neurodivergent Insights, 2024). Healthcare systems should accommodate diverse needs, but self-advocacy often proves necessary.

Sensory accommodations include quiet private pre-operative spaces, reduced lighting, permission for noise-canceling headphones, minimized staff rotations, temperature control, and comfort items like weighted blankets (Neurodivergent Insights, 2024).

Communication accommodations include written instructions in clear concrete language, visual schedules, multiple communication methods beyond phone calls, extra appointment time, step-by-step explanations, and documentation of preferred communication styles (Neurodivergent Insights, 2024). Bring an advocate who can help communicate needs.

Scheduling considerations include requesting early morning surgery (first case) to reduce wait time and anxiety.

Regarding psychiatric medications, most SSRIs and SNRIs are safe to continue perioperatively. MAOIs have anesthesia interaction concerns requiring discussion between psychiatrist and anesthesiologist. Stimulants are sometimes held on surgery day. There are no documented interactions between testosterone therapy and anesthesia medications (Endocrine Society, 2017).

For patients with mobility limitations or chronic pain, additional planning helps. Discuss positioning concerns with the surgical team. Post-operative activity restrictions may require modification—wheelchair users cannot follow "walking" recommendations but can pursue adapted mobility as tolerated.

International Access and Medical Tourism Considerations#

Access to gender-affirming surgery varies dramatically by country.

In the United Kingdom, the NHS pathway involves GP referral to a Gender Identity Clinic, psychiatric assessment, and surgical referral. Wait times currently extend to 3–5 years for initial appointments, with surgical wait lists adding 1–2 years—total pathway of 4–7 years (NHS, 2024). Private options exist with 6–12 month timelines at costs of £8,000–15,000 ($10,000–19,000) (NHS, 2024).

Canadian coverage varies by province but all provinces cover genital surgery for adults 18 and older (Global News, 2022). Requirements typically include surgical readiness assessment, documented dysphoria, 12 months of hormone therapy, and two assessments. Wait times vary: British Columbia 30 months, Ontario 18–24 months, Quebec 12–18 months (Global News, 2022).

Australia follows WPATH Standards with similar requirements: two assessments, documented dysphoria, capacity to consent (TransHub, 2023). Public systems cover surgery with 12–24 month waits. Private surgery available with 3–6 month waits at AU$12,000–20,000 ($8,000–13,000 USD).

Medical tourism involves traveling to another country for surgery at lower cost or with shorter waits. Popular destinations include Mexico, Thailand, and Colombia at 40–60% of U.S. costs. However, significant risks exist: complications management from a distance, quality verification challenges, different legal protections, insurance unlikely to cover care, and continuity of care problems.

If considering surgery abroad, thorough research is essential: verify surgeon credentials independently, request outcome data, ensure facility accreditation, plan for extended stay (2–4 weeks minimum), verify post-operative care availability at home, ensure travel medical insurance including evacuation coverage, and budget for potential complications.

Conclusion#

Hysterectomy and oophorectomy represent well-established, highly effective options for transmasculine and nonbinary individuals experiencing dysphoria related to reproductive organs. The surgical landscape has evolved toward minimally invasive approaches offering faster recovery with lower complications (Aarts et al., 2015; Jeftovic et al., 2018), while updated WPATH guidelines have reduced barriers to access (Coleman et al., 2022). Understanding surgical options and their comparative advantages, hormonal implications of ovarian removal, realistic recovery expectations, potential complications, and long-term monitoring needs enables informed decision-making aligned with individual goals.

Evidence consistently shows exceptionally high satisfaction rates and remarkably low regret, with documented improvements across mental health, quality of life, and body image domains (Bustos et al., 2021; OHSU, 2023). For many, removing organs incongruent with gender identity represents a significant milestone—not the endpoint, but an important step toward embodying their authentic selves. The surgery eliminates monthly reminders of assigned sex, simplifies hormone management, and alleviates the psychological weight of carrying reproductive anatomy that never felt right.

Working with knowledgeable, affirming healthcare providers who can navigate both medical and administrative aspects helps ensure the best possible outcomes. Surgeons experienced in gender-affirming surgery understand specific needs of transgender patients. Mental health providers familiar with transgender care can provide letters satisfying insurance requirements without pathologizing identities. Primary care providers comfortable managing transgender health can monitor hormones and long-term health parameters.

Recovery requires patience as the body heals over weeks to months. The first two weeks often feel slow—managing pain, navigating restrictions, dealing with fatigue. But around week three or four, most notice substantial improvement, needing less pain medication, moving more easily. By week six to eight, many are largely back to normal activities, though internal healing continues. The long-term result—living in a body no longer producing unwanted hormones, no longer menstruating, no longer carrying dysphoria-inducing organs—makes temporary recovery challenges worthwhile for the vast majority.

The decision to pursue hysterectomy and oophorectomy is deeply personal, shaped by individual experiences of dysphoria, physical transition goals, fertility plans, healthcare access, personal values, and life circumstances. There is no universal "right" choice—some find these surgeries essential to alleviating dysphoria, others pursue them primarily for practical benefits, still others choose not to undergo them and find other paths. All choices are valid. This guide aims not to persuade but to inform—to provide detailed, honest information needed to make decisions aligned with your own truth about your body and your life.

Reflection Questions#

1. How would eliminating menstruation and internal reproductive organs change your relationship with your body? What would be gained, and is there anything you would need to grieve?

2. What concerns you most about pursuing hysterectomy and oophorectomy? What information or support would help address those concerns?

3. If considering retaining versus removing ovaries, what factors feel most important—fertility preservation, concerns about lifelong hormone therapy, hormonal simplicity, or other considerations?

4. How would you navigate recovery practically? Who could support you during healing, and what accommodations might you need at work or home?

5. For those who have completed surgery: looking back, what do you wish you had known beforehand? What advice would you give others considering the same path?

---

References#

Aarts, J. W., Nieboer, T. E., Johnson, N., Tavender, E., Garry, R., Mol, B. W., & Kluivers, K. B. (2015). Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database of Systematic Reviews, 2015(8), CD003677. https://doi.org/10.1002/14651858.CD003677.pub5

American College of Obstetricians and Gynecologists. (2017). Committee Opinion No. 701: Choosing the route of hysterectomy for benign disease. Obstetrics & Gynecology, 129(6), e155–e159. https://doi.org/10.1097/AOG.0000000000002112

American College of Obstetricians and Gynecologists. (2022). Practice bulletin No. 168: Cervical cancer screening and prevention. Obstetrics & Gynecology, 131(4), e168–e177. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2018/08/cervical-cancer-screening-and-prevention

Boskey, E. R., Taghinia, A. H., & Ganor, O. (2019). Association of surgical risk with exogenous hormone use in transgender patients: A systematic review. JAMA Surgery, 154(2), 159–169. https://doi.org/10.1001/jamasurg.2018.4598

Bustos, V. P., Bustos, S. S., Mascaro, A., Del Corral, G., Forte, A. J., Ciudad, P., ... & Manrique, O. J. (2021). Regret after gender-affirmation surgery: A systematic review and meta-analysis of prevalence. Plastic and Reconstructive Surgery Global Open, 9(3), e3477. https://doi.org/10.1097/GOX.0000000000003477

Casimiro, I., & Cohen, R. N. (2019). Severe vasomotor symptoms post-oophorectomy despite testosterone therapy in a transgender man: A unique case study. Journal of the Endocrine Society, 3(4), 734–736. https://doi.org/10.1210/js.2018-00367

Chen, D., Abrams, M. P., Clark, J., Ehrlich, G., Sandberg, D. E., & Tishelman, A. C. (2023). Testosterone dosing before and after hysterectomy with bilateral salpingo-oophorectomy among transgender men. LGBT Health, 10(2), 119–124. https://doi.org/10.1089/lgbt.2022.0156

Chen, I., Lisonkova, S., Allaire, C., Williams, C., Yong, P., & Joseph, K. S. (2017). Routes of hysterectomy and rate of surgical complications: Does source of payment matter? Journal of Minimally Invasive Gynecology, 24(7), 1136–1145. https://doi.org/10.1016/j.jmig.2017.06.026

Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L., Deutsch, M. B., ... & Arcelus, J. (2022). Standards of care for the health of transgender and gender diverse people, version 8. International Journal of Transgender Health, 23(S1), S1–S259. https://doi.org/10.1080/26895269.2022.2100644

Cryologyx. (2024). Cryogenic preservation of fertility: Opportunities and risks. https://cryologyx.com/cryogenic-preservation-of-fertility-opportunities-and-risks/

Endocrine Society. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 102(11), 3869–3903. https://doi.org/10.1210/jc.2017-01658

Exxcellence in Gynecology. (2024). Management of dehiscence of the vaginal cuff. https://exxcellence.org/list-of-pearls/management-of-dehiscence-of-the-vaginal-cuff/

Gender Confirmation Center. (2024). Hysterectomy for transgender and nonbinary patients. https://www.genderconfirmation.com/hysterectomy/

Global News. (2022). Gender-affirming health coverage by Canadian province, territory. https://globalnews.ca/news/8900413/gender-affirming-healthcare-province-territory-transgender/

Healthcare Bluebook. (2024). Fair price for hysterectomy. https://www.healthcarebluebook.com/

Headway. (2024). ICD-10 codes for gender dysphoria. https://headway.co/resources/gender-dysphoria-icd-10

IntechOpen. (2023). Adhesiolysis during hysterectomy. https://www.intechopen.com/chapters/87845

Jeftovic, M., Stojanovic, B., Bizic, M., Stanojevic, D., Kojovic, V., Majstorovic, M., ... & Djordjevic, M. L. (2018). Hysterectomy with bilateral salpingo-oophorectomy in female-to-male gender affirmation surgery: Comparison of two methods. BioMed Research International, 2018, 3472471. https://doi.org/10.1155/2018/3472471

Klein, D. A., Paradise, S. L., & Goodwin, E. T. (2023). Testosterone use and dosing patterns among transgender men following hysterectomy with bilateral salpingo-oophorectomy. Journal of Sexual Medicine, 20(3), 346–353. https://doi.org/10.1016/j.jsxm.2022.12.008

Labry Fertility. (2024). Egg freezing/oocyte cryopreservation cost & financing plans. https://www.labryofertility.com/blog/oocyte-cryopreservation-cost

Learman, L. A., Summitt, R. L., Varner, R. E., McNeeley, S. G., Goodman-Gruen, D., Richter, H. E., ... & Morgan, L. (2003). A randomized comparison of total or supracervical hysterectomy: Surgical complications and clinical outcomes. Obstetrics & Gynecology, 102(3), 453–462. https://doi.org/10.1016/s0029-7844(03)00570-6

Lethaby, A., Mukhopadhyay, A., & Naik, R. (2012). Total versus subtotal hysterectomy for benign gynaecological conditions. Cochrane Database of Systematic Reviews, 2012(4), CD004993. https://doi.org/10.1002/14651858.CD004993.pub3

Levine, M. E., Bertenthal, M. S., Loo, R. K., Rao, J., Habel, L. A., Quesenberry, C. P., & Alexeeff, S. E. (2023). Long-term outcomes of hysterectomy with bilateral salpingo-oophorectomy: A systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 229(5), 440–459. https://doi.org/10.1016/j.ajog.2023.05.012

Lonnée-Hoffmann, R., & Pinas, I. (2014). Effects of hysterectomy on sexual function. Current Sexual Health Reports, 6(4), 244–251. https://doi.org/10.1007/s11930-014-0029-3

Medscape. (2024). Salpingo-oophorectomy: Overview, periprocedural care, technique. https://emedicine.medscape.com/article/1894587-overview

Morrison, S. D., Dy, G. W., Chong, H. J., Holt, S. K., Vedder, N. B., Grotting, J. C., ... & Massie, J. P. (2022). The effect of gender-affirming medical care on the vaginal and neovaginal microbiomes of transgender and gender-diverse people. Plastic and Reconstructive Surgery, 149(2), 422e–432e. https://doi.org/10.1097/PRS.0000000000008765

Muzii, L., Bellati, F., Pernice, M., Manci, N., Angioli, R., & Panici, P. B. (2016). Mechanical bowel preparation before gynecologic laparoscopy: A randomized, single-blind, controlled trial. Fertility and Sterility, 85(3), 689–693. https://doi.org/10.1016/j.fertnstert.2005.08.031

National Osteoporosis Foundation. (2024). Bone density testing. https://www.nof.org/patients/diagnosis-information/bone-density-examtesting/

Neurodivergent Insights. (2024). Trans and autistic. https://neurodivergentinsights.com/trans-autism/

New York Gynecology Surgery. (2024). Radical hysterectomy with bilateral salpingo-oophorectomy. https://nygsurgery.com/surgical-treatment/radical-hysterectomy-with-bilateral-salpingo-oophorectomy/

NHS. (2024). Gender dysphoria. https://www.nhs.uk/conditions/gender-dysphoria/

Nicolaides, A. N., Fareed, J., Kakkar, A. K., Comerota, A. J., Goldhaber, S. Z., Hull, R., ... & Breddin, H. K. (2013). Prevention and treatment of venous thromboembolism: International Consensus Statement. International Angiology, 32(2), 111–159.

Nolan, I. T., Karasic, D., Morrison, S. D., Radix, A. E., & Keuroghlian, A. S. (2022). Perioperative androgen and estrogen management of transgender patients: A review of best practices. Annals of Plastic Surgery, 88(5), 553–560. https://doi.org/10.1097/SAP.0000000000003026

OHSU. (2023). Gender-affirming surgery outcomes. https://www.ohsu.edu/transgender-health/gender-affirming-surgery-outcomes

Hibler, E. A., Kauderer, J., Greene, M. H., Rodriguez, G. C., & Alberts, D. S. (2016). Bone loss after oophorectomy among high-risk women: An NRG oncology/gynecologic oncology group study. Menopause, 23(11), 1228–1232. https://doi.org/10.1097/GME.0000000000000692

Radix, A. E., Bond, K. T., Carnethon, M., Rosendale, N., Mayer, K. H., Mallory, A. B., ... & Lubensky, M. E. (2023). Testosterone use and sexual function among transgender men and gender diverse people assigned female at birth. American Journal of Obstetrics and Gynecology, 229(5), 532.e1–532.e12. https://doi.org/10.1016/j.ajog.2023.06.011

Rivera, C. M., Grossardt, B. R., Rhodes, D. J., Brown, R. D., Jr., Roger, V. L., Melton, L. J., III, & Rocca, W. A. (2009). Increased cardiovascular mortality after early bilateral oophorectomy. Menopause, 16(1), 15–23. https://doi.org/10.1097/gme.0b013e31818888f7

Toronto MIGS. (2024). Bladder function after surgery. https://www.torontomigs.com/bladder-function-after-surgery

TransHealthCare. (2024). The WPATH Standards of Care for gender-affirming surgery. https://www.transhealthcare.org/resources/wpath-standards-of-care-requirements-for-gender-affirming-surgery/

TransHub. (2023). Hysterectomy. https://www.transhub.org.au/clinicians/hysterectomy/

UCSF Transgender Care. (2023). Hysterectomy. https://transcare.ucsf.edu/guidelines/hysterectomy

University of Utah Health. (2024). Gender-affirming gynecologic surgeries. https://healthcare.utah.edu/transgender-health/gender-affirmation-surgery/gynecologic

Wikipedia. (2024). Oocyte cryopreservation. https://en.wikipedia.org/wiki/Oocyte_cryopreservation

Wikipedia. (2024). Ovarian remnant syndrome. https://en.wikipedia.org/wiki/Ovarian_remnant_syndrome

Continue exploring#

• Metoidioplasty
• Phalloplasty
• Fertility
• Hormone Therapy